CN Patent

CN106632145B — 沃替西汀氢溴酸盐晶型α的新制备方法

Assigned to Jiangsu Hansoh Pharmaceutical Group Co Ltd · Expires 2021-11-05 · 5y expired

What this patent protects

本发明涉及沃替西汀氢溴酸盐晶型α的新制备方法，其包括如下步骤：将沃替西汀氢溴酸盐溶解在良溶剂中，低温下滴加至不良溶剂中，析晶得到晶型α。该方法具有收率高、纯度高、耗能低、操作简单、安全环保、重现性好等优点，特别适合医药化工行业大规模化工生产的要求。

USPTO Abstract

本发明涉及沃替西汀氢溴酸盐晶型α的新制备方法，其包括如下步骤：将沃替西汀氢溴酸盐溶解在良溶剂中，低温下滴加至不良溶剂中，析晶得到晶型α。该方法具有收率高、纯度高、耗能低、操作简单、安全环保、重现性好等优点，特别适合医药化工行业大规模化工生产的要求。

Drugs covered by this patent

vortioxetine-hydrobromide (VORTIOXETINE HYDROBROMIDE)

Patent Metadata

Patent number: CN106632145B
Jurisdiction: CN
Classification: —
Expires: 2021-11-05
Drug substance claim: No
Drug product claim: No
Assignee: Jiangsu Hansoh Pharmaceutical Group Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.